Table 2.
Baseline characteristics
| No. of patients (n = 93) | |
|---|---|
| Age in years (median, range) | 64 (26–83) |
| Gender (male:female) | 47 : 46 |
| Preadmission body mass index (BMI) (median, IQR) | 25.5 (22.6–29.2) |
| Referral | |
|
Internal External |
15 (16.1%) 78 (83.9%) |
| Time between last abdominal intervention and first visit (T1) in months (median, IQR) | 2 (1-5) |
| Diabetes Mellitus | 17 (18.3%) |
| Smoking | 17 (18.3%) |
| IBD | 18 (19.4%) |
| Immunosuppressive medication | 8 (8.6%) |
| Number of previous abdominal operations (median, IQR) | 4 (3–7) |
| Etiology type 2 intestinal failure | |
|
ECF# Anastomotic leakage Perforation iatrogenic Mesh related Perforation inflammatory / infection± Ischemic bowel Other^ EAF* after open abdomen treatment High output enterostomy Anastomotic leakage Perforation iatrogenic Perforation inflammatory/infection± Ischemic bowel Oncologic resection Radiation enteritis |
39 (41.9%) 15 (16.1%) 9 (9.7%) 5 (5.4%) 5 (5.4%) 1 (1.1%) 4 (4.2%) 15 (16.1%) 37 (39.8%) 9 (9.7%) 1 (1.1%) 7 (7.5%) 19 (20.4%) 1 (1.1%) 2 (2.2%) |
| High-output fistula or stoma | 69 (74.2%) |
| Small bowel length to enterostomy/fistula | |
|
< 50 cm 50–100 cm 100–150 cm 150–200 cm 200–250 cm > 250 cm |
3 (3.2%) 9 (9.7%) 16 (17.2%) 9 (9.7%) 5 (5.4%) 51 (54.8%) |
| Colon length | |
|
< Hemicolon in situ Ileocaecal valve in situ |
35 (37.6%) 56 (60.2%) |
| Central catheter at first visit | |
|
None CVC1 PICC2 Port-a-cath |
2 (2.1%) 55 (59.2%) 34 (36.6%) 2 (2.1%) |
#Enterocutaneous fistula
±Inflammatory bowel disease/pancreatitis/diverticulitis
^After open abdomen treatment/oncologic resection/unknown
*Enteroatmospheric fistula
1Central venous catheter
2Peripheral inserted central catheter